Asthma and COPD Drug Market Report 2025 (Global Edition)

Global Asthma and COPD Drug Market Report 2025 Market Size Split by Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), by End User (Asthma Patients, COPD ...

Asthma and COPD Drug Market Report Description

We have various report editions of Asthma and COPD Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Asthma and COPD Drug Market Insights Video

Competitive Landscape of the Asthma and COPD Drug Market

The major players rapidly evolve with new strategies to attain a competitive edge and capture significant market share. The major asthma and COPD drug market participants emphasize expanding creative offerings to serve a large consumer base and gain a competitive benefit.

Asthma and COPD Drug Industry News

• In June 2022, Glenmark introduced a unique fixed dose combination (FDC) medication called Indacaterol + Mometasone for Indian patients with very severe asthma. The FDC was marketed under the trade name Indamet.

(Source: www.livemint.com/companies/news/glenmark-launches-fixed-dose-combination-drug-for-asthma-patients-in-india-11655355777360.html)

Top Companies Market Share in Asthma and COPD Drug Industry: (In no particular order of Rank)

• GlaxoSmithKline Plc
• Merck & Co Inc
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Grifols S.A.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Asthma and COPD Drug Market

According to Cognitive Market Research, North America dominated the market in 2023 and accounted for around 5.00% of the global revenue, owing to the ageing population, the prevalence of diseases like asthma and COPD, the rise in research and development efforts, and the existence of major market players   In the US, adult women are more likely than adult males to have asthma. In Canada, asthma is a significant public health issue. Asthma is a chronic respiratory condition that impairs a person's ability to work, their quality of life, their mental health, and their psychological well-being in Canada. Due to the large number of asthma sufferers, there is a greater need for medications to treat the condition, which propels the expansion of this area. 

Europe is the fastest-growing category as the key market participants' presence in the area, including Teva Pharmaceutical Industries, AstraZeneca, and GlaxoSmithKline. These businesses have a considerable market share and make large investments in R&D to create novel and cutting-edge medications and drug delivery systems. In addition, the area boasts a strong healthcare infrastructure that fosters the creation and uptake of novel treatments. This infrastructure includes cutting-edge diagnostic and treatment centers. Furthermore, the overall revenue is rising due to the increase in the number of programs that both government and non-government organizations are pursuing.

The current report Scope analyzes Asthma and COPD Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Asthma and COPD Drug Market

According to Cognitive Market Research, the global Asthma and COPD Drug market size was estimated at USD 34512.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 13804.88 million in 2023 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2023 to 2030. It is anticipated that the increase in money committed by both government and non-government entities will stimulate market expansion in this area.  According to Cognitive Market Research, this kind of investment is probably going to raise awareness of asthma, which is going to boost medicine uptake for asthma therapy, which is going to spur vertical growth. The modern healthcare infrastructure and the local presence of major pharmaceutical companies are anticipated to drive market growth. In conclusion, the North American asthma and COPD drug market is thriving due to the rise in research and development efforts aimed at creating new treatments are all contributing to the market's growth.

• According to Cognitive Market Research, the US had a major share in the asthma and COPD drug market with a market size of USD 10892.05 million in 2023 and is projected to grow at a CAGR of 3.0% during the forecast period due to the growing hospital population and high population density.
• The Canada asthma and COPD drug market had a market share of USD 1656.59 million in 2023 and is projected to grow at a CAGR of 4.0% during the forecast period due to the existence of important manufacturing players, a tobacco-smoking habit, and a developed infrastructure.
• The Mexico asthma and COPD drug market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 1256.24 million in 2023.

Europe Asthma and COPD Drug Market

According to Cognitive Market Research, with a market value of USD 34512.2 million in 2023 and projected to expand at a compound annual growth rate (CAGR) of 3.6% from 2023 to 2030, Europe accounted for a share of over 30% of the global market size of USD 10353.6 million due to presence of significant actors for manufacturing, tobacco smoking habit, and well-established infrastructure in the region. According to Cognitive Market Research, increase in the number of hospitals and large population. Furthermore, profitable prospects are expected to be presented to the industry by technology improvements. In conclusion, the North American asthma and COPD drug market is thriving due to the development of innovative targeted medications, which will be encouraged by the limitations of standard treatments, such as their low efficacy and delayed beginning of action.

• According to Cognitive Market Research, the German asthma and COPD drug market size was valued at USD 2050.02 million in 2023 and is projected to grow at a CAGR of 3.7% during the forecast period. The principal parties engaged in partnerships, mergers and acquisitions, new product creation, and growth tactics to increase market penetration.  
• The United Kingdom asthma and COPD drug market had a market share of USD 1739.41 million in 2023 and is projected to grow at a CAGR of 4.3% during the forecast period due to the government is making significant investments in the creation of novel pharmaceuticals.
• The France asthma and COPD drug market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD 952.54 million in 2023.
• The Italy asthma and COPD drug market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 890.41 million in 2023.
• The Russian asthma and COPD drug market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 1604.82 million in 2023.
• The Spain asthma and COPD drug market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 849.00 million in 2023.
• The Portugal asthma and COPD drug market is projected to witness growth at a CAGR of 3.3% during the forecast period with a market size of USD 217.43 million in 2023.
• The Luxembourg asthma and COPD drug market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 320.96 million in 2023.
• The Greece asthma and COPD drug market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 124.24 million in 2023.
• The Rest of Europe's asthma and COPD drug market is projected to witness growth at a CAGR of 2.2% during the forecast period with a market size of USD 1604.82 million in 2023.

Asia Pacific Asthma and COPD Drug Market

According to Cognitive Market Research, the global Asthma and COPD Drug market size was estimated at USD 34512.2 Million out of which Asia Pacific held the market of more than 23% of the global revenue with a market size of USD 7937.81 million in 2023 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2023 to 2030 due to availability of numerous bronchodilators and combination therapies, as well as technological developments in drug delivery systems. According to Cognitive Market Research, the development of targeted treatments and biologics is anticipated to further propel market expansion. Additionally, there is fierce competition in the asthma market due to the high demand for new drug entrants in combinational therapy, beta-agonists, and inhaled corticosteroids. In conclusion, the North American asthma and COPD drug market is thriving due to the several potential opportunities in the asthma and COPD industry as the majority of large organizations are focussing on contract manufacturing outsourcing (CMO).

• According to Cognitive Market Research, the China asthma and COPD drug market size was valued at USD 3572.01 million in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period. The existence of important manufacturing players, a tobacco-smoking habit, and a developed infrastructure.
• The India asthma and COPD drug market had a market share of USD 952.54 million in 2023 and is projected to grow at a CAGR of 8.8% during the forecast period due to numerous studies that have shown that people with COPD and asthma can now benefit from combination medications.
• The Japan asthma and COPD drug market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 1095.42 million in 2023.
• The South Korean asthma and COPD drug market is projected to witness growth at a CAGR of 6.1% during the forecast period with a market size of USD 793.78 million in 2023.
• The Australian asthma and COPD drug market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 412.77 million in 2023.
• The South East Asia asthma and COPD drug market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD 547.71 million in 2023.
• The Rest of Asia Pacific's asthma and COPD drug market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD 563.58 million in 2023.

South America Asthma and COPD Drug Market

According to Cognitive Market Research, the global Asthma and COPD Drug market size was estimated at USD 34512.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 1725.61 million in 2023 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2023 to 2030 due to the availability of a large variety of medications, medical technological improvements, and rising disease awareness all have an impact on the market. The market is growing as more people become aware of respiratory health issues and the treatments that are available. According to Cognitive Market Research, proactive healthcare activities combined with educational campaigns enable people to find and take effective medication, which creates a favorable market environment. The increase in market value is largely due to technological advancements in the pharmaceutical industry. conclusion, the Latin American asthma and COPD drug market exhibits steady growth, driven by the effectiveness of asthma and COPD treatments is improved by innovations in drug delivery technologies and formulations, which boosts patient and market satisfaction.

• According to Cognitive Market Research, the Brazil asthma and COPD drug market size was valued at USD 738.56 million in 2023 and is projected to grow at a CAGR of 5.0% during the forecast period. Both lung function and the avoidance of asthma attacks are aided by inhaled corticosteroids (ICS). 
• The Argentina asthma and COPD drug market had a market share of USD 289.90 million in 2023 and is projected to grow at a CAGR of 5.3% during the forecast period due to numerous studies that have shown that people with COPD and asthma can now benefit from combination medications.
• The Colombia asthma and COPD drug market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 153.58 million in 2023.
• The Peru asthma and COPD drug market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 141.50 million in 2023.
• The Chile asthma and COPD drug market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 124.24 million in 2023.
• The Rest of Latin America's asthma and COPD drug market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 277.82 million in 2023.

Middle East Asthma and COPD Drug Market

According to Cognitive Market Research, the global Asthma and COPD Drug market size was estimated at USD 34512.2 Million out of which Middle East and Africa held the major market of more than 2% of the global revenue with a market size of USD 690.24 million in 2023 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030. The worldwide market for asthma and COPD medications is expanding as a result of the rising prevalence of asthma. The global market for asthma and COPD medications is expanding due to the aging population. According to Cognitive Market Research, the government is making significant investments in the creation of novel pharmaceuticals. A few government agencies are working with industry participants to introduce innovative products. In conclusion, the MEA (Middle East and Africa) asthma and COPD drug market exhibits growth potential due to the aforementioned reasons are driving the growth of the global market for asthma and COPD medications.

• According to Cognitive Market Research, the GCC Countries asthma and COPD drug market size was valued at USD 295.42 million in 2023 and is projected to grow at a CAGR of 5.5% during the forecast period due to the steady rise in the use of medicine and pharmaceutical combinations to treat a wide range of diseases. 
• The South Africa asthma and COPD drug market had a market share of USD 109.06 million in 2023 and is projected to grow at a CAGR of 5.7% during the forecast period due to numerous studies have shown that people with COPD and asthma can now benefit from combination medications.
• The Egypt asthma and COPD drug market is projected to witness growth at a CAGR of 5.0% during the forecast period with a market size of USD 72.48  million in 2023.
• The Turkey asthma and COPD drug market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 59.36 million in 2023.
• The Nigeria asthma and COPD drug market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 72.48 million in 2023.
• The Rest of MEA asthma and COPD drug market is projected to witness growth at a CAGR 3.7% during the forecast period with a market size of USD 81.45 million in 2023.

Asthma and COPD Drug Market Analysis

Asthma and COPD Drug Drug Class Segment Analysis

According to Cognitive Market Research, monoclonal antibodies held the major market share over the forecast period.  Treatment with monoclonal antibodies that target interleukin (IL)-5 and its receptor (IL-5R) may be beneficial for people with chronic obstructive pulmonary disease (COPD) who use oral corticosteroids (OCS) to manage their symptoms. Treatment with nti–IL-5/IL-5R may lessen OCS reliance and COPD exacerbations.

Bronchodilators are the fastest-growing category over the forecast period. A class of drugs known as bronchodilators helps people with asthma and COPD breathe more easily by relaxing the muscles in their airways. The rising incidence of COPD and asthma, which has raised demand for efficient and practical therapies is driving the market growth. The market has expanded due to the availability of numerous bronchodilators and combination therapies, as well as technological developments in drug delivery systems. In the upcoming years, the development of targeted treatments and biologics is anticipated to further propel market expansion.

• Bronchodilators
• Monoclonal Antibodies
• Anti-Inflammatory Drugs
• Combination Drugs

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Asthma and COPD Drug Industry. Request a Free Sample PDF!

Asthma and COPD Drug Application Segment Analysis

According to Cognitive Market Research, asthma patients hold a prominent market share. The symptoms of asthma, a long-term respiratory condition marked by inflammation and airway constriction, include wheezing, coughing, and shortness of breath. The availability of a large variety of medications and combination therapies, as well as rising public awareness of the condition, are the main drivers of the asthma medication market. The creation of more convenient and effective therapies has been made possible by technological improvements in drug delivery methods and formulations, which have an impact on the market. In the upcoming years, the introduction of biologics and tailored treatments is anticipated to significantly accelerate market expansion. 

COPD Patients is the fastest-growing category over the forecast period. A primary cause of COPD is smoking. While smoking rates have been dropping in many parts of the world, there are still forecast considerable numbers of smokers, particularly in low- and middle-income countries. It is estimated that rising rates of COPD patients are driving the demand for asthma and COPD medications.

• Asthma Patients
• COPD Patients

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Asthma and COPD Drug Distribution Channel Segment Analysis

According to Cognitive Market Research, hospital pharmacies hold a prominent market share. Hospitalisation may be necessary for respiratory conditions including asthma and COPD, especially in more severe situations. Hospital pharmacies are likely to see a rise in demand for asthma and COPD medications as a result of the illnesses' rising prevalence and subsequent hospitalizations.  Asthma-related hospital admissions rose during the COVID-19 epidemic in a number of nations worldwide. According to the study, during the pandemic, hospital admissions for asthma rose by 30–70% in these nations.

General pharmacies are the fastest-growing category over the forecast period. Patients find it more convenient to purchase medications from general pharmacies because there are more of them than hospital pharmacies. Additionally, after their doctors have recommended a medication, individuals with COPD and asthma typically make additional purchases at retail pharmacies.

• General Pharmacies
• Hospital Pharmacies
• Online Retailers

Asthma and COPD Drug Therapy Segment Analysis

According to Cognitive Market Research, preventive hold a prominent market share. Using daily or routine drugs to lessen the frequency and intensity of asthma symptoms, stop asthma episodes, and enhance lung function is the standard of care for asthma patients undergoing preventive therapy. People whose asthma is not effectively controlled with simply short-term drugs (like albuterol) or those who have symptoms regularly are usually advised to pursue preventive therapy.

Curative is the fastest-growing category over the forecast period. Many therapies and treatments, including oxygen therapy, inhaled corticosteroids, oral steroids, and bronchodilators, are available to assist control and relieve symptoms as curative therapies for asthma and COPD treatment. For COPD and asthma, it is critical to collaborate with a healthcare professional to identify the most efficient and secure course of treatment.

• Preventive
• Curative

Asthma and COPD Drug Route Of Administration Segment Analysis

According to Cognitive Market Research, oral holds a prominent market share. Tablets like Zafirlukast, Foradil, and Symbicort are used as the oral route of delivery. The industry is anticipated to develop as a result of shorter treatment times. Additionally, this administration method is the least costly, most practical, and safest, all of which contribute to its growing popularity and the expansion of the market. For the most part, oral administration is recommended while treating acute asthma. It is also preferred when treating children's asthma and COPD because they have trouble using inhalers.

Inhaled is the fastest-growing category over the forecast period. A nebulizer, dry powder inhaler, or an inhaler can be used to provide drugs that are inhaled. Inhalers administer medication in a pressurized canister, while nebulizers use a machine to transform liquid medication into a tiny mist that may be inhaled. Medication can be inhaled to transport the medication straight to the lungs, where it will be swiftly absorbed and begin to operate.

• Oral
• Inhaled
• Intravenous
• Subcutaneous

Asthma and COPD Drug Age Group Segment Analysis

According to Cognitive Market Research, below 5 hold a prominent market share. Since their airways are smaller and more susceptible to blockage by mucus or inflammation in children under the age of 5, asthma in these patients can be more challenging to diagnose. All ages are susceptible to asthma, a chronic lung condition that can even strike newborns and early children.

5-14 is the fastest-growing category over the forecast period. In children, asthma is one of the most prevalent respiratory disorders between the ages of 5-14. Children in this age range who have asthma are generally treated with a daily controller drug, such as an inhaled corticosteroid, which helps to lessen airway inflammation.

• Below 5
• 5-14
• 15-60
• Above 60

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion